Compare Ascendis Pharma A/S (ASND) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Gilead Sciences, Inc. — how do they compare? Ascendis Pharma A/S trades at $253.76 (market cap $16.67B), while Gilead Sciences, Inc. trades at $135.41 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is far larger — about 10.1× Ascendis Pharma A/S's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | GILD | |
|---|---|---|
Market Cap | $16.67B | $168.35B |
Sector | Health | Health |
52-Week High | $277.18 | $155.80 |
52-Week Low | $189.74 | $110.56 |
Enterprise Value | $17.04B | $191.42B |
Dividend Yield | — | 2.42% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
